Researcher
Els Van Nieuwenhuysen
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Department of Oncology (Department)
Member
From1 Sep 2015 → 31 Oct 2017 - Gynaecological Oncology (Division)
Member
From1 Aug 2012 → Today
Projects
1 - 4 of 4
- ORDECA – ORganoid Drug screening for Endometrial CAncerIdentifying novel drugs and biomarkers for treating endometrial cancer using a high-throughput patient-derived organoid drug discovery and screening platformFrom1 Oct 2023 → TodayFunding: IOF - technology validation in lab
- Abemaciclib and letrozole in ER positive rare ovarian cancerFrom1 Mar 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Efficacy of abemaciclib and letrozole in estrogen receptor-positive rare ovarian cancer and unravelling mechanisms of response and resistanceFrom1 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → 1 Apr 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
11 - 20 of 101
- Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.(2023)
Authors: Els Van Nieuwenhuysen
Pages: 1698 - 1707 - Bowel obstruction in advanced tubo-ovarian cancer: a retrospective cohort study(2023)
Authors: Eva Oldenburger, Albert Wolthuis, Els Van Nieuwenhuysen, Patrick Neven, Ignace Vergote, Sileny Han
Pages: 1539 - 1545 - CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study(2023)
Authors: Diether Lambrechts, Liselore Loverix, Toon Van Gorp, Els Van Nieuwenhuysen, Ignace Vergote
Pages: 697 - 713 - Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci(2022)
Authors: Diether Lambrechts, Els Van Nieuwenhuysen
Pages: 1533 - 1544 - Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)(2022)
Authors: Els Van Nieuwenhuysen
Pages: 3080 - 3089 - Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).(2022)
Authors: Els Van Nieuwenhuysen
- Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group(2022)
Authors: Ignace Vergote, Els Van Nieuwenhuysen, Toon Van Gorp
Pages: 753 - 760 - Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer(2022)
Authors: Pieter Busschaert, Siel Olbrecht, An Coosemans, Wouter Froyman, Liselore Loverix, Els Van Nieuwenhuysen, Sileny Han, Toon Van Gorp, Tom Venken, Ruben Heremans, et al.
- Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer(2022)
Authors: Liselore Loverix, Pieter Busschaert, Els Van Nieuwenhuysen, Sileny Han, Siel Olbrecht, Patrick Neven, Diether Lambrechts, Toon Van Gorp, Ignace Vergote
Pages: 14 - 22 - TRP channel expression correlates with the epithelial-mesenchymal transition and high-risk endometrial carcinoma(2022)
Authors: Katrien De Clercq, Daniela Annibali, Frédéric Amant, Sileny Han, Els Van Nieuwenhuysen, Thaïs Baert, Karen Peeraer, Thomas Voets, Toon Van Gorp, Joris Vriens